Sunvozertinib Demonstrates Promise for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
According to results from a pooled analysis of phase 1/2 studies, sunvozertinib, an oral, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), demonstrated promise among patients with EGFR-mutated non-small cell lung cancer (NSCLC) who developed resistance to EGFR TKIs.
“Current standard first-line treatment consists of either upfront third-generation EGFR TKI or sequential treatment with first- or second-generation EGFR TKI followed by a third-generation EGFR TKI when EGFR T790M mutation is detected,” stated Mengzhao Wang, MD, Peking Union Medical College Hospital, Beijing, China, and coauthors. “However, acquired resistance to EGFR TKI inevitably occurred driven by EGFR-dependent or EGFR-independent mechanisms.”
In this study, researchers collected data from 40 patients enrolled in WU-KONG1, WU-KONG2, and WU-KONG15 who received 50 mg to 400 mg of once daily sunvozertinib. Primary end points included objective response rate (ORR), disease control rate, duration of response (DOR), progression-free survival (PFS), and safety. Baseline plasma specimens were collected to analyze EGFR mutations and alterations in the EGFR downstream signaling pathway.
At analysis, the best ORR was 27.5% and the best disease control rate was 60%. The median DOR was 6.5 months and the median PFS was 6 months. Among patients who last received chemotherapy, the ORR was 31.6% compared to 14.3% among patients who last received an EGFR TKI. The ORR for patients with EGFR sensitizing and T790M double mutations was 55.6%. Safety was consistent with prior findings.
As Dr Wang et al concluded, “Sunvozertinib has promising activity implying future investigations in the patients with EGFR mutated NSCLC who developed resistance to prior EGFR TKI.”
Source:
Wang M, Xu Y, Huang WT, et al. Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations. Lung Cancer. Published online: December 2, 2024. doi: 10.1016/j.lungcan.2024.108053
